Naltrexone pharmacotherapy
ApprovedSmall molecule
Naltrexone pharmacotherapy is one of 11 small molecule programs targeting Pathological Gambling. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Pathological Gambling
#DrugCompanyPhaseTrials
1Campral
FForest Laboratories
Approved
Topamax
WWim Janssens
Phase 3
Zyprexa
MMODAG GmbH
Phase 3
Namenda
FForest Laboratories
Phase 2
Naltrexone pharmacotherapy
FFinnish Institute for Health and Welfare
Approved
Nalmefene Hcl
PPurdue Pharma LP
Phase 3
Revia
TevaPreclinical
N-Acetyl Cyteien
SStanford University
Phase 1
Milk Thistle
UUniversity of Chicago
Phase 2
Wellbutrin
GGlaxo Dba Glaxosmithkline
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Naltrexone pharmacotherapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details